LGALS3 and hydrops fetalis: Whether treat-to-biomarker approaches (e.g., sST2-guided intensification, Gal-3-focused antifibrotic strategies, nuanced interpretation of GDF-15 as a stress/adaptation index) translate into fewer HF events remains a critical question for practical trials.